Chi-Med License Accord for Cancer Drug Probable This Year

Hutchison China MediTech Ltd., the drugmaker controlled by Hong Kong billionaire Li Ka-shing, is in talks to license a cancer treatment based on traditional Chinese medicines, Chief Executive Officer Christian Hogg said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.